Oncology "big-wig" for sure ...
Daniel D. Von Hoff is the physician in chief and director of translational research at Translational Genomics Research Institute (TGen), and current Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute. He is also a professor of medicine at the Mayo Clinic and medical director of research as well as chief scientific officer at US Oncology. He is most notable for his work in targeted therapies for the treatment of cancer.[1] He led the development of gemcitabine,[2] and has several drugs in development.
Ann: Distinguished Oncologist Daniel Von Hoff Joins as Consultant, page-3
-
- There are more pages in this discussion • 166 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.76 |
Change
-0.070(3.83%) |
Mkt cap ! $311.7M | |||
| Open | High | Low | Value | Volume |
| $1.82 | $1.82 | $1.76 | $34.67K | 19.21K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 519 | $1.76 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 340 | 1 |
View Market Depth
| Last trade - 10.43am 22/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |